Motor dysfunctions in Parkinson's disease are considered to be primarily due to the
degeneration of dopaminergic neurons in the substantia nigra pars compacta …

Clinical studies with intrastriatal transplants of human embryonic mesencephalic tissue have
provided proof-of-principle for the cell replacement strategy in Parkinson's disease (PD) …

Early clinical trials designed to treat Parkinson's disease by transplantation of fetal tissue
containing dopamine neuron precursors yielded promising results, but the approach retains …

Parkinson's disease (PD) is a neurodegenerative condition which causes a characteristic
movement disorder secondary to loss of dopaminergic neurons in the substanitia nigra. The …

The main pathology underlying motor symptoms in Parkinson's disease (PD) is a rather
selective degeneration of nigrostriatal dopamine (DA) neurons. Intrastriatal transplantation …

Stem cell replacement has emerged as the novel therapeutic strategy for Parkinson's
disease (PD). Control of motor behavior is lost in PD due to the selective degeneration of …

Parkinson's disease (PD) is the most common movement disorder. The neuropathology is
characterized by the loss of dopamine neurons in the substantia nigra pars compacta …

The ability to successfully replace lost nigral dopaminergic neurons in Parkinson's disease
(PD) has been clearly shown with fetal ventral mesencephalic transplants, albeit …

Parkinson disease (PD) is characterized by loss of the A9 nigral neurons that provide
dopaminergic innervation to the striatum. This discovery led to the successful instigation of …

Cell replacement therapy has been proposed as a means of replacing specific populations
of cells lost through trauma, disease or ageing. Parkinson's disease is a progressive …